Clinical Trial Update: Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Extension of the Phase 3 QTI571A2301 trial evaluating imatinib for severe pulmonary arterial hypertension to assess long-term safety, tolerability, and efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2015-05-21